2023 World Conference on Lung Cancer (Posters)-EP12.01. A Real World Cohort Study of First Line Afatinib in Patients with EGFR mutant Advanced Non Small Cell Lung Cancer in Vietnam

EP12.01. A Real World Cohort Study of First Line Afatinib in Patients with EGFR mutant Advanced Non Small Cell Lung Cancer in Vietnam - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to investigate the effectiveness and tolerability of afatinib as a first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations in Vietnamese patients. The study included 343 patients from nine hospitals in Vietnam who received afatinib between April 2018 and June 2022. The majority of patients had adenocarcinoma, while a small number had squamous cell or adenosquamous cell carcinoma. The most common EGFR mutation was Del19, followed by L858R and other uncommon mutations. Approximately one-fourth of patients had brain metastases at baseline. <br /><br />The overall response rate (ORR) to afatinib treatment was 78.1% in the overall population, with similar response rates observed in different EGFR mutation subgroups. The median time-to-treatment failure (TTF) was 16.7 months, with longer TTF observed in patients with common EGFR mutations and without brain metastases. The starting dose of afatinib did not significantly affect TTF.<br /><br />The most common treatment-related adverse events were diarrhea, rash, paronychia, and stomatitis. About 23.3% of patients required dose reductions due to tolerability issues.<br /><br />In conclusion, afatinib demonstrated promising effectiveness and tolerability in Vietnamese patients with EGFR-mutant NSCLC. Administering a starting dose below 40mg may lead to a slight reduction in the response rate but does not significantly impact TTF. This real-world cohort study provides valuable insights into the use of afatinib as a targeted therapy for NSCLC in a Vietnamese population.

Asset Subtitle

Phuong Pham

Meta Tag

Speaker Phuong Pham

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

afatinib

first-line treatment

NSCLC

EGFR mutations

Vietnamese patients

adenocarcinoma

Del19 mutation

brain metastases

response rate

tolerability